Fax: (011) 44-0115-9627768
The prognostic significance of lymphovascular invasion in invasive breast carcinoma
Article first published online: 16 DEC 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 15, pages 3670–3680, 1 August 2012
How to Cite
Rakha, E. A., Martin, S., Lee, A. H. S., Morgan, D., Pharoah, P. D. P., Hodi, Z., MacMillan, D. and Ellis, I. O. (2012), The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer, 118: 3670–3680. doi: 10.1002/cncr.26711
- Issue published online: 20 JUL 2012
- Article first published online: 16 DEC 2011
- Manuscript Accepted: 24 OCT 2011
- Manuscript Revised: 4 OCT 2011
- Manuscript Received: 24 AUG 2011
- invasive breast carcinoma;
- lymphovascular invasion;
- lymph node status;
Although lymphovascular invasion (LVI) has been associated with a poor outcome in patients with breast cancer, it is not included in most internationally recognized staging systems, including the American Joint Committee on Cancer tumor, lymph node, metastasis (TNM) classification. This is mainly because it remains unclear whether the presence of LVI is an independent, high-risk criterion in clinically relevant staging subgroups.
The current study was based on a large and well characterized consecutive series of patients who had operable (pathologic T1 [pT1]-pT2, pathologic N0 [pN0]-pN3, M0) breast cancer (3812 informative cases) who were treated according to standard protocols at a single institution and who had long-term follow-up to assess the prognostic value of definite LVI in clinically and molecularly relevant staging subgroups.
LVI was strongly associated with both breast cancer-specific survival (BCSS) and distant metastasis-free survival (DMFS) in the entire series and in different subgroups. Multivariate analyses identified LVI as an independent predictor of both BCSS and DMFS in patients with operable breast cancer overall; in the TNM clinical subgroups pT1a-pT1c/pN0 and pT2/pN0; and in the molecular classes estrogen receptor (ER)-positive, ER-negative, human epidermal growth factor 2 [HER2]-negative, and triple-negative. In patients who had lymph node-negative tumors, LVI could be used as a high-risk criterion providing survival disadvantage equivalent to that provided by 1 or 2 involved lymph nodes (pN0 to pN1) and to that provided by 1 size category (pT1 to pT2). The use of immunohistochemistry for detecting an endothelial-specific marker contributed to the prognostic significance of LVI when applied to routine LVI negative/possible cases.
LVI provided a strong predictor of outcome in patients with invasive breast cancer and should be incorporated into breast cancer staging systems. Cancer 2012. © 2011 American Cancer Society.